Lead sponsor
Allergan
1 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
1
Trials led
0
Ongoing
0
Total enrollment
6
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
1
Trials by status
Withdrawn
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's DiseaseAlzheimer's diseasePh 1Withdrawnnot disclosed